WATERTOWN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug…
The option agreement grants NLS Pharmaceutics Ltd. the exclusive option to in-license all of Aexon Labs' assets for the potential…
Expanse Oncology the next step toward creating a single, patient-centered EHRCANTON, Mass.--(BUSINESS WIRE)--St. Joseph’s/Candler Health System (Savannah, GA) has taken…
-- Company on track to submit PAS-004 IND application in current quarter -- -- Pasithea plans to begin PAS-004 Phase 1 dose…
Event will focus on tavapadon, a D1/D5 partial agonist in Phase 3 development for the treatment of Parkinson’s disease Live…
NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor, a clinically validated target for the treatment…
VANCOUVER, British Columbia, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB:…
BURLINGTON, Mass. and JERUSALEM, Nov. 20, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),…
Advances novel monoclonal antibody designed to be highly selective for toxic oligomers of amyloid-beta (Aβ) in first-in-human studyTORONTO, Ontario and CAMBRIDGE,…
Rebranded company to DMK Pharmaceuticals and appointed inaugural, passionate and committed leadership team to execute on new strategy to reduce…